Government Updates

2009-03-21 > All chapters

China denies Coca-Cola decision equals trade protectionism

BEIJING - China's Ministry of Commerce (MOC) Thursday denied its refusal to approve Coca-Cola's acquisition of Huiyuan Juice Group is protectionist.

Read more
2009-03-21 > All chapters

Emission tariff proposal an excuse for protectionism

The country's top climate change official has rejected a proposal by the United States to slap tariffs on imports from countries that do not impose costs on carbon emissions.

Read more
2009-03-20 > All chapters

SCLAO, CNTA: Held Press Conference for “Travel Agencies Regulations”- The Whole Industry Will Se

SCLAO, CNTA: Held Press Conference for “Travel Agencies Regulations”- The Whole Industry Will Seriously Implement the Regulations

Read more
2009-03-20 > All chapters

MIIT: Prints 2009 Administrative Major Tasks for Strengthening Safety Production of Industry and Com

MIIT: Prints 2009 Administrative Major Tasks for Strengthening Safety Production of Industry and Communications Industry

Read more
2009-03-20 > All chapters

MOH: Circular of Printing “Administrative Measures for Clinical Application of Medical Technology

MOH: Circular of Printing “Administrative Measures for Clinical Application of Medical Technology”

Read more
2009-03-20 > All chapters

MOF: Issues Administrative Measures for the Transfer of State-Owned Assets of Financial Enterprises

MOF: Issues Administrative Measures for the Transfer of State-Owned Assets of Financial Enterprises

Read more
2009-03-20 > All chapters

MOFCOM: Announcement No. 22 [2009]

MOFCOM: Announcement No. 22 [2009]

Read more
2009-03-20 > All chapters

Revised rules 'help lift travel market'

The move to slash the amount of capital needed by foreign-owned travel agencies to set up in China will further widen the market and help reduce rogue operators, said senior tourism officials yesterday.

Read more
2009-03-20 > All chapters

China tightens regulations on risky medical technologies

BEIJING - China is tightening regulations on the clinical use of high-risk or ethically controversial diagnostic and therapeutic technologies.

Read more